Cortisol responses to the insulin hypoglycaemia test in children

P M Crofton1, A C Don-Wauchope, L E Bath

  • 1Department of Paediatric Biochemistry, Royal Hospital for Sick Children, Edinburgh, UK. patricia.crofton@luht.scot.nhs.uk

Hormone Research
|December 3, 2003
PubMed

Insights

The peak cortisol response in children during the insulin hypoglycemia (IH) test occurs by 90 minutes. This response is age-dependent, with younger children showing higher peak cortisol levels.

Area of Science:

  • Pediatric Endocrinology
  • Endocrine Testing
  • Hormone Physiology

Background:

  • The insulin hypoglycemia (IH) test is a standard method for assessing the hypothalamic-pituitary-adrenal (HPA) axis in children.
  • Establishing precise reference data for cortisol response timing is crucial for accurate pediatric endocrine diagnostics.

Purpose of the Study:

  • To determine the peak cortisol response timing during the IH test in pediatric patients.
  • To establish normative pediatric reference data for cortisol levels following IH testing.
  • To investigate the relationship between age and peak cortisol response in children.

Main Methods:

  • Retrospective review of IH tests in children under 16 years at a tertiary pediatric endocrine center.
  • Inclusion criteria: adequate hypoglycemia (glucose ≤ 2.0 mmol/l), exclusion of patients with HPA axis impairment or on glucocorticoids.
  • Blood samples analyzed for glucose, cortisol, and growth hormone at multiple time points post-insulin injection.

Main Results:

  • Peak cortisol and growth hormone (GH) responses were observed within 90 minutes in all subjects.
  • A significant inverse correlation was found between peak cortisol and age (rs -0.65, p<0.0001).
  • Median peak cortisol was higher in children younger than 10 years (689 nmol/l) compared to older children (555 nmol/l).

Conclusions:

  • The IH test sampling protocol in children can be shortened, with peak cortisol response identified by 90 minutes.
  • Peak cortisol response to IH testing is significantly influenced by age in pediatric populations.
  • These findings provide valuable reference data for pediatric endocrine assessment.
Abstract

Related Concept Videos

Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
Hypoglycemia01:26

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...